In lung and colorectal cancer, high expression and secretion of serglycin is associated with a poor clinical outlook and treatment resistance (Xu et al., 2018), while the knock-down of serglycin decreases tumor burden in vivo (Guo et al., 2017). This evidence concerns the gene SRGN and neoplasm.